Considerations for second-line therapy of non-small cell lung cancer.

@article{Stinchcombe2008ConsiderationsFS,
  title={Considerations for second-line therapy of non-small cell lung cancer.},
  author={Thomas E. Stinchcombe and Mark A. Socinski},
  journal={The oncologist},
  year={2008},
  volume={13 Suppl 1},
  pages={
          28-36
        }
}
For patients with advanced non-small cell lung cancer and a good functional status, platinum-based first-line chemotherapy improves quality of life, reduces disease-related symptoms, and improves survival. The addition of bevacizumab to carboplatin and paclitaxel in the first-line setting has been shown to produce a higher response rate and longer progression-free survival and overall survival times than with carboplatin and paclitaxel. Despite these therapies, all patients inevitably… CONTINUE READING
Highly Cited
This paper has 61 citations. REVIEW CITATIONS
Tweets
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 47 citations

62 Citations

0510'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 62 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 57 references